Trial · NCT03296527
Registered outcomes61
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 61
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Circulating Concentrations of Estradiol | On stimulation Day 6 | Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels on stimulation Day 6 are presented. |
| Secondary | Circulating Concentrations of Estradiol | End-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels at end-of-stimulation are presented. |
| Secondary | Circulating Concentrations of Progesterone | On stimulation Day 6 | Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels on stimulation Day 6 are presented. |
| Secondary | Circulating Concentrations of Progesterone | End-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels at end-of-stimulation are presented. |
| Secondary | Circulating Concentrations of Inhibin A | On stimulation Day 6 | Blood samples for analysis of circulating concentrations of inhibin A. The median and IQR of inhibin A levels on stimulation Day 6 are presented. |
| Secondary | Circulating Concentrations of Inhibin A | End-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of inhibin A were drawn. The median and IQR of inhibin A levels at end-of-stimulation are presented. |
| Secondary | Circulating Concentrations of Inhibin B | On stimulation Day 6 | Blood samples for analysis of circulating concentrations of Inhibin B were drawn. The median and IQR of inhibin B levels on stimulation Day 6 are presented. |
| Secondary | Circulating Concentrations of Inhibin B | End-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of Inhibin B were drawn. The median and IQR of inhibin B levels at end-of-stimulation are presented. |
| Secondary | Circulating Concentrations of Follicle-stimulating Hormone (FSH) | On stimulation Day 6 | Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels on stimulation Day 6 are presented. |
| Secondary | Circulating Concentrations of FSH | End-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels at end-of-stimulation are presented. |
| Secondary | Circulating Concentrations of FSH | At oocyte retrieval | Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels at oocyte retrieval are presented. |
| Secondary | Total Gonadotropin Dose | Up to 20 stimulation days | Calculated by start dates, end dates and daily dose of IMP. |
| Secondary | Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments | Up to 20 stimulation days | Investigator-requested decreases and increases of the gonadotropin dose were captured during the stimulation period. |
| Secondary | Number of Stimulation Days | Up to 20 stimulation days | Calculated by start dates and end dates. |
| Secondary | Number of Participants With Adverse Events | From screening up to end-of-trial (up to approximately 5.5 months) | Any adverse event occurring after start of IMP and before the end-of-trial visit, or a pre-treatment adverse event or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit was considered treatment-emergent, and is presented for this endpoint. |
| Secondary | Intensity of Adverse Events | From screening up to end-of-trial (up to approximately 5.5 months) | The intensity of adverse event was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity; moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable). |
| Secondary | Changes From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase and Gamma glutamyl transferase. |
| Secondary | Change From Baseline in Clinical Chemistry Parameters: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium | From screening up to end-of-trial (approximately 5.5 months) | Blood samples were collected for the analysis of clinical chemistry parameters including: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium. |
| Secondary | Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein | From screening up to end-of-trial (approximately 5.5 months) | Blood samples were collected for the analysis of clinical chemistry parameters including: Albumin and Protein. |
| Secondary | Change From Baseline in Clinical Chemistry Parameter: Lactate Dehydrogenase | From screening up to end-of-trial (approximately 5.5 months) | Blood samples were collected for the analysis of clinical chemistry parameter including: Lactate dehydrogenase. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296527/registered?page=2